OncoMatch/Clinical Trials/NCT06262139
Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
Is NCT06262139 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies MT218 for mri scan.
Treatment: MT218 — This phase 1b open label, dose-escalating investigation study is to evaluate the dose dependent initial efficacy of the use of MT218 injection for biomarker targeted MR molecular imaging (MRMI) of prostate cancer in patients scheduled for radical prostatectomy.
Check if I qualifyExtracted eligibility criteria
Lab requirements
Kidney function
GFR > 60 mL/min within 30 days of research MRI; no diagnosis of active acute, chronic, or sub-chronic kidney disease
Liver function
No diagnosis of active acute, chronic, or sub-chronic liver disease
Glomerular filtration rate (GFR) > 60 mL/min within a 30 days of the research MRI. Any diagnosis of active acute, chronic, or sub-chronic kidney or liver disease [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory University · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify